New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:49 EDTBCRXBioCryst, HHS extend peramivir agreement for 31 days
BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
10:00 EDTBCRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:26 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTBCRXBioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill
As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both Ď4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.
06:00 EDTBCRXBioCryst upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use